Clinical Trial

A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics（PD）and anti-drug antibodies（ADA） of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-05-16; most recent amendment 2025-08-14.
Status change: Recruiting → Active, Not Recruiting 2025-05-27
Status change: Not Yet Recruiting → Recruiting 2023-08-09
Trial Details
NCT Number NCT05862233
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions Primary Membranous Nephropathy
Enrollment 150 participants
Start Date 2023-06-02
Primary Completion 2025-05-13 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-20